Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL

Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL

Abstract IDH1 and IDH2 mutations (IDH1/2 Mut ) are recognized as recurrent genetic alterations in acute myeloid leukemia (AML) and associated with both clinical impact and therapeutic opportunity due to the recent development of specific IDH1/2 Mut inhibitors. In T-cell acute lymphoblastic leukemia...

Full description

Bibliographic Details
Main Authors: Mathieu Simonin, Aline Schmidt, Christophe Bontoux, Marie-Émilie Dourthe, Etienne Lengliné, Guillaume P. Andrieu, Ludovic Lhermitte, Carlos Graux, Nathalie Grardel, Jean-Michel Cayuela, Françoise Huguet, Isabelle Arnoux, Stéphane Ducassou, Elizabeth Macintyre, Virginie Gandemer, Hervé Dombret, Arnaud Petit, Norbert Ifrah, André Baruchel, Nicolas Boissel, Vahid Asnafi
Format: Article
Language:English
Published: BMC 2021-05-01
Series:Journal of Hematology & Oncology
Subjects:
IDH1
IDH2
T-ALL
Online Access:https://doi.org/10.1186/s13045-021-01068-4

Internet

https://doi.org/10.1186/s13045-021-01068-4

Similar Items